港股收评：恒生科技指数涨0.9%，建材板块走强

Market Overview - The Hang Seng Index closed up 0.31%, the Hang Seng Tech Index rose 0.9%, and the Hang Seng China Enterprises Index increased by 0.28% [1] Construction Sector - The construction sector showed strong performance, with China National Building Material rising over 11%, Huaneng International up over 6%, and China Resources Cement Technology increasing by over 5% [1] - Key stock movements include: - China National Building Material (3323) at 6.320 HKD, up 11.46% [1] - Huaneng International (1102) at 0.047 HKD, up 6.82% [1] - China Resources Cement Technology (1313) at 1.980 HKD, up 5.32% [1] Metals Sector - The metals sector also saw gains, with Jiaxin International Resources up over 11%, Xinjiang Xin Mining up over 10%, and Xinyuan Wanheng Holdings increasing by 10% [2] - Notable stock performances include: - Jiaxin International Resources (3858) at 92.200 HKD, up 11.22% [2] - Xinjiang Xin Mining (3833) at 2.730 HKD, up 10.08% [2] - Xinyuan Wanheng Holdings (2326) at 0.011 HKD, up 10% [2] Chemical Sector - The chemical sector experienced a strong rally, with Zhongwei New Materials rising over 11%, Zhongqi Group up over 7%, and Ximei Resources increasing by over 6% [3] - Key stock movements include: - Zhongwei New Materials (2579) at 37.820 HKD, up 11.50% [3] - Zhongqi Group (1932) at 0.290 HKD, up 7.41% [3] - Ximei Resources (dasse) at 10.230 HKD, up 6.23% [3] Consumer Durables Sector - The consumer durables sector weakened, with Han Cheng Development Holdings, Baiyue Group, and Pop Mart all declining over 5% [4] - Key stock performances include: - Han Cheng Development Holdings (0361) at 0.085 HKD, down 5.56% [4] - Baiyue Group (8545) at 0.034 HKD, down 5.56% [4] - Pop Mart (9992) at 255.000 HKD, down 5.49% [4] Individual Stock Movements - Yueda Group fell over 8%, reaching a low of 39.88 HKD per share, following a profit warning indicating a projected loss of approximately 750 million to 850 million RMB for 2025 [4] - The loss is attributed to goodwill impairment from the acquisition of New Classics Media in 2018, which is a non-cash expense and will not affect cash flow [4] Strategic Partnerships - InSilico Medicine saw a midday surge of nearly 8%, closing at 73.2 HKD after announcing a strategic partnership with Kangzheng Pharmaceutical for drug development in central nervous system and autoimmune diseases [5] - The collaboration will involve at least two AI-enabled drug development projects, with potential funding of several tens of millions of HKD for each project [5]